B BEAM THERAPEUTICS INC
| Market Cap | $2.80B |
| P/E Ratio | — |
| Forward P/E | -6.41 |
| Dividend Yield | — |
| Beta | 2.17 |
| 52W Range | $13.53 - $36.44 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 0.00% | $0 | 0 | Sold |
Insider Trading
| Insider Name of the company insider who made the trade 22 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| John M. EvansCEO | Sale | 25,000 | $22.76 | $569.09K | 31 Mar 2026 | 01 Apr 2026 |
| John M. EvansCEO | Sale | 25,000 | $22.37 | $559.23K | 30 Mar 2026 | 01 Apr 2026 |
| Ciaramella GiuseppePresident | Sale | 35,000 | $32.00 | $1.12M | 24 Feb 2026 | 26 Feb 2026 |
| Evans John M.CEO | Sale | 22,094 | $28.27 | $624.67K | 30 Jan 2026 | 02 Feb 2026 |
| Evans John M.CEO | Sale | 2,906 | $29.00 | $84.27K | 30 Jan 2026 | 02 Feb 2026 |
| John M. EvansCEO | Sale | 2,906 | $29.00 | $84.27K | 30 Jan 2026 | 02 Feb 2026 |
| John M. EvansCEO | Sale | 22,094 | $28.27 | $624.67K | 30 Jan 2026 | 02 Feb 2026 |
| Evans John M.CEO | Sale | 8,667 | $29.74 | $257.78K | 29 Jan 2026 | 02 Feb 2026 |
| Evans John M.CEO | Sale | 16,333 | $29.19 | $476.80K | 29 Jan 2026 | 02 Feb 2026 |
| John M. EvansCEO | Sale | 8,667 | $29.74 | $257.78K | 29 Jan 2026 | 02 Feb 2026 |
| John M. EvansCEO | Sale | 16,333 | $29.19 | $476.80K | 29 Jan 2026 | 02 Feb 2026 |
| Bellon ChristineChief Legal Officer | Sale | 1,371 | $34.00 | $46.61K | 22 Jan 2026 | 26 Jan 2026 |
| Cavanagh Bethany JSVP, Finance and Treasurer | Sale | 6,198 | $35.00 | $216.93K | 22 Jan 2026 | 26 Jan 2026 |
| Cavanagh Bethany JSVP, Finance and Treasurer | Sale | 3,034 | $30.12 | $91.38K | 20 Jan 2026 | 21 Jan 2026 |
| Bellon ChristineChief Legal Officer | Sale | 559 | $35.40 | $19.79K | 15 Jan 2026 | 20 Jan 2026 |
| Bellon ChristineChief Legal Officer | Sale | 15,959 | $34.72 | $554.07K | 15 Jan 2026 | 20 Jan 2026 |
| Bellon ChristineChief Legal Officer | Sale | 2,111 | $33.62 | $70.98K | 15 Jan 2026 | 20 Jan 2026 |
| Bellon ChristineChief Legal Officer | Sale | 1,254 | $27.10 | $33.98K | 31 Dec 2025 | 05 Jan 2026 |
| Emany Sravan KumarChief Financial Officer | Sale | 6,294 | $27.10 | $170.57K | 31 Dec 2025 | 05 Jan 2026 |
| Sravan Kumar EmanyChief Financial Officer | Sale | 6,294 | $27.10 | $170.57K | 31 Dec 2025 | 05 Jan 2026 |
| Christine BellonChief Legal Officer | Sale | 1,254 | $27.10 | $33.98K | 31 Dec 2025 | 05 Jan 2026 |
| FMR LLCOther, 10% Owner | Sale | 459 | $26.68 | $12.25K | 27 Oct 2025 | 29 Oct 2025 |
Frequently Asked Questions
What is BEAM stock price today?
BEAM THERAPEUTICS INC (BEAM) is currently trading at $27.45. The stock has a 52-week range of $13.53 to $36.44 and a market capitalization of $2.80B.
Is BEAM a good stock to buy in 2026?
BEAM THERAPEUTICS INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +5.1%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling BEAM stock?
There have been 22 insider transactions for BEAM in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has BEAM stock performed over the past year?
BEAM THERAPEUTICS INC (BEAM) has returned +5.1% over the past 12 months. The stock traded between $13.53 and $36.44 during this period, and is currently at $27.45.
Which hedge funds own BEAM (BEAM THERAPEUTICS INC)?
1 tracked hedge funds currently hold BEAM in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is BEAM's market cap and valuation?
BEAM THERAPEUTICS INC (BEAM) has a market capitalization of $2.80B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is BEAM's revenue and profitability?
BEAM THERAPEUTICS INC reported revenue of $139.74M with net income of N/A and a profit margin of N/A. The stock has a beta of 2.17.
What sector is BEAM in and who are its biggest institutional holders?
BEAM THERAPEUTICS INC (BEAM) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.